Cargando…
Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
OBJECTIVE: Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancer...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322129/ https://www.ncbi.nlm.nih.gov/pubmed/37159554 http://dx.doi.org/10.1093/oncolo/oyad105 |
_version_ | 1785068688877027328 |
---|---|
author | Xavier, Camila B Link, Rudinei Abreu, Leonília Bettoni, Fabiana Marson, Fabiane Galante, Pedro A F Masotti, Cibele Amano, Mariane T de Molla, Vinicius Camargo, Anamaria A Asprino, Paula F Sabbaga, Jorge |
author_facet | Xavier, Camila B Link, Rudinei Abreu, Leonília Bettoni, Fabiana Marson, Fabiane Galante, Pedro A F Masotti, Cibele Amano, Mariane T de Molla, Vinicius Camargo, Anamaria A Asprino, Paula F Sabbaga, Jorge |
author_sort | Xavier, Camila B |
collection | PubMed |
description | OBJECTIVE: Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancers at later ages, who harbored a likely pathogenic TP53 at low allele frequency detected in a blood sample. METHODS: The Molecular Tumor Board committee at our institution revisited the case of a patient who was enrolled in a research protocol for the investigation of genetic conditions associated with neuroendocrine tumors. Clinical, familial, and molecular data were reviewed. The patient received germline testing using a next generation sequencing multi-gene panel and was incidentally found to harbor a TP53 likely pathogenic variant, with 22% of variant allele fraction. Additional samples, including a second blood sample, oral swab, and saliva, were collected for DNA analysis. A new TP53 sequencing round was performed with the attempt to distinguish between a true constitutional germline variant and a somatically acquired variant due to aberrant clonal expansion of bone marrow precursors. RESULTS: Patient’s personal and familial history of cancer did not meet classic nor Chompret LFS criteria. Environmental risk factors for cancer were identified, such as alcohol abuse and tobacco exposure. The TP53 variant initially found in the next-generation sequencing was confirmed by Sanger sequencing in the previous DNA sample extracted from blood for the first analysis and in a second blood sample collected 6 years later. The TP53 variant was not detected in the DNA extracted from the oral swab and saliva samples. CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution. |
format | Online Article Text |
id | pubmed-10322129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103221292023-07-06 Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board Xavier, Camila B Link, Rudinei Abreu, Leonília Bettoni, Fabiana Marson, Fabiane Galante, Pedro A F Masotti, Cibele Amano, Mariane T de Molla, Vinicius Camargo, Anamaria A Asprino, Paula F Sabbaga, Jorge Oncologist Precision Medicine Clinic: Molecular Tumor Board OBJECTIVE: Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancers at later ages, who harbored a likely pathogenic TP53 at low allele frequency detected in a blood sample. METHODS: The Molecular Tumor Board committee at our institution revisited the case of a patient who was enrolled in a research protocol for the investigation of genetic conditions associated with neuroendocrine tumors. Clinical, familial, and molecular data were reviewed. The patient received germline testing using a next generation sequencing multi-gene panel and was incidentally found to harbor a TP53 likely pathogenic variant, with 22% of variant allele fraction. Additional samples, including a second blood sample, oral swab, and saliva, were collected for DNA analysis. A new TP53 sequencing round was performed with the attempt to distinguish between a true constitutional germline variant and a somatically acquired variant due to aberrant clonal expansion of bone marrow precursors. RESULTS: Patient’s personal and familial history of cancer did not meet classic nor Chompret LFS criteria. Environmental risk factors for cancer were identified, such as alcohol abuse and tobacco exposure. The TP53 variant initially found in the next-generation sequencing was confirmed by Sanger sequencing in the previous DNA sample extracted from blood for the first analysis and in a second blood sample collected 6 years later. The TP53 variant was not detected in the DNA extracted from the oral swab and saliva samples. CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution. Oxford University Press 2023-05-09 /pmc/articles/PMC10322129/ /pubmed/37159554 http://dx.doi.org/10.1093/oncolo/oyad105 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Precision Medicine Clinic: Molecular Tumor Board Xavier, Camila B Link, Rudinei Abreu, Leonília Bettoni, Fabiana Marson, Fabiane Galante, Pedro A F Masotti, Cibele Amano, Mariane T de Molla, Vinicius Camargo, Anamaria A Asprino, Paula F Sabbaga, Jorge Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board |
title | Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board |
title_full | Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board |
title_fullStr | Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board |
title_full_unstemmed | Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board |
title_short | Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board |
title_sort | suspected germline tp53 variants and clonal hematopoiesis of indeterminate potential: lessons learned from a molecular tumor board |
topic | Precision Medicine Clinic: Molecular Tumor Board |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322129/ https://www.ncbi.nlm.nih.gov/pubmed/37159554 http://dx.doi.org/10.1093/oncolo/oyad105 |
work_keys_str_mv | AT xaviercamilab suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT linkrudinei suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT abreuleonilia suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT bettonifabiana suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT marsonfabiane suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT galantepedroaf suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT masotticibele suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT amanomarianet suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT demollavinicius suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT camargoanamariaa suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT asprinopaulaf suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard AT sabbagajorge suspectedgermlinetp53variantsandclonalhematopoiesisofindeterminatepotentiallessonslearnedfromamoleculartumorboard |